Financhill
Sell
49

CKPT Quote, Financials, Valuation and Earnings

Last price:
$3.14
Seasonality move :
-13.84%
Day range:
$3.07 - $3.21
52-week range:
$1.38 - $4.50
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
831.1K
Avg. volume:
1.9M
1-year change:
65.45%
Market cap:
$154.3M
Revenue:
$103K
EPS (TTM):
-$1.84

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
CKPT
Checkpoint Therapeutics
$4.5M -- 72.17% -- $18.00
FBIO
Fortress Biotech
$15.6M -$0.75 -21.91% -41.51% $14.33
IBIO
iBio
-- -$0.39 -100% -89.82% $3.60
NBY
NovaBay Pharmaceuticals
$3M -$0.31 -60.77% -99.16% $7.30
PTN
Palatin Technologies
-- -$0.46 -100% -25% --
TOVX
Theriva Biologics
-- -$5.50 -- -8.25% --
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
CKPT
Checkpoint Therapeutics
$3.16 $18.00 $154.3M -- $0.00 0% --
FBIO
Fortress Biotech
$2.03 $14.33 $56M -- $0.00 0% 0.40x
IBIO
iBio
$2.55 $3.60 $23.3M -- $0.00 0% --
NBY
NovaBay Pharmaceuticals
$0.70 $7.30 $3.4M -- $0.00 0% 0.07x
PTN
Palatin Technologies
$1.13 -- $22.1M -- $0.00 0% --
TOVX
Theriva Biologics
$1.45 -- $4M -- $0.00 0% 1.59x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
CKPT
Checkpoint Therapeutics
-- 3.829 -- 0.23x
FBIO
Fortress Biotech
71.75% 0.808 900.37% 0.99x
IBIO
iBio
4.41% 8.236 5.41% 3.89x
NBY
NovaBay Pharmaceuticals
4.54% 0.365 1.51% 0.75x
PTN
Palatin Technologies
-- -3.016 -- 0.99x
TOVX
Theriva Biologics
-- -1.870 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
CKPT
Checkpoint Therapeutics
-- -$9.7M -- -- -16275.61% -$11.2M
FBIO
Fortress Biotech
$9.3M -$22.1M -94.06% -- -166.72% -$20.1M
IBIO
iBio
-- -$4.1M -90.99% -148.3% -1820.57% -$3.7M
NBY
NovaBay Pharmaceuticals
$1.6M -$1.1M -334.47% -461.38% -44% -$2.1M
PTN
Palatin Technologies
$350K -$7.8M -- -- -2356.3% -$7M
TOVX
Theriva Biologics
-- -$5M -- -- -- -$3.9M

Checkpoint Therapeutics vs. Competitors

  • Which has Higher Returns CKPT or FBIO?

    Fortress Biotech has a net margin of -16268.29% compared to Checkpoint Therapeutics's net margin of -87.96%. Checkpoint Therapeutics's return on equity of -- beat Fortress Biotech's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    CKPT
    Checkpoint Therapeutics
    -- -$0.23 -$15.7M
    FBIO
    Fortress Biotech
    63.87% -$0.76 $41M
  • What do Analysts Say About CKPT or FBIO?

    Checkpoint Therapeutics has a consensus price target of $18.00, signalling upside risk potential of 469.62%. On the other hand Fortress Biotech has an analysts' consensus of $14.33 which suggests that it could grow by 606.08%. Given that Fortress Biotech has higher upside potential than Checkpoint Therapeutics, analysts believe Fortress Biotech is more attractive than Checkpoint Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    CKPT
    Checkpoint Therapeutics
    2 0 0
    FBIO
    Fortress Biotech
    1 0 0
  • Is CKPT or FBIO More Risky?

    Checkpoint Therapeutics has a beta of 1.361, which suggesting that the stock is 36.073% more volatile than S&P 500. In comparison Fortress Biotech has a beta of 1.670, suggesting its more volatile than the S&P 500 by 66.964%.

  • Which is a Better Dividend Stock CKPT or FBIO?

    Checkpoint Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fortress Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Checkpoint Therapeutics pays -- of its earnings as a dividend. Fortress Biotech pays out -14.46% of its earnings as a dividend.

  • Which has Better Financial Ratios CKPT or FBIO?

    Checkpoint Therapeutics quarterly revenues are $41K, which are smaller than Fortress Biotech quarterly revenues of $14.6M. Checkpoint Therapeutics's net income of -$9.7M is higher than Fortress Biotech's net income of -$12.9M. Notably, Checkpoint Therapeutics's price-to-earnings ratio is -- while Fortress Biotech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Checkpoint Therapeutics is -- versus 0.40x for Fortress Biotech. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CKPT
    Checkpoint Therapeutics
    -- -- $41K -$9.7M
    FBIO
    Fortress Biotech
    0.40x -- $14.6M -$12.9M
  • Which has Higher Returns CKPT or IBIO?

    iBio has a net margin of -16268.29% compared to Checkpoint Therapeutics's net margin of -4444.57%. Checkpoint Therapeutics's return on equity of -- beat iBio's return on equity of -148.3%.

    Company Gross Margin Earnings Per Share Invested Capital
    CKPT
    Checkpoint Therapeutics
    -- -$0.23 -$15.7M
    IBIO
    iBio
    -- -$0.46 $22.3M
  • What do Analysts Say About CKPT or IBIO?

    Checkpoint Therapeutics has a consensus price target of $18.00, signalling upside risk potential of 469.62%. On the other hand iBio has an analysts' consensus of $3.60 which suggests that it could grow by 41.18%. Given that Checkpoint Therapeutics has higher upside potential than iBio, analysts believe Checkpoint Therapeutics is more attractive than iBio.

    Company Buy Ratings Hold Ratings Sell Ratings
    CKPT
    Checkpoint Therapeutics
    2 0 0
    IBIO
    iBio
    1 0 0
  • Is CKPT or IBIO More Risky?

    Checkpoint Therapeutics has a beta of 1.361, which suggesting that the stock is 36.073% more volatile than S&P 500. In comparison iBio has a beta of -3.266, suggesting its less volatile than the S&P 500 by 426.584%.

  • Which is a Better Dividend Stock CKPT or IBIO?

    Checkpoint Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iBio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Checkpoint Therapeutics pays -- of its earnings as a dividend. iBio pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CKPT or IBIO?

    Checkpoint Therapeutics quarterly revenues are $41K, which are smaller than iBio quarterly revenues of $175K. Checkpoint Therapeutics's net income of -$9.7M is lower than iBio's net income of -$4M. Notably, Checkpoint Therapeutics's price-to-earnings ratio is -- while iBio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Checkpoint Therapeutics is -- versus -- for iBio. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CKPT
    Checkpoint Therapeutics
    -- -- $41K -$9.7M
    IBIO
    iBio
    -- -- $175K -$4M
  • Which has Higher Returns CKPT or NBY?

    NovaBay Pharmaceuticals has a net margin of -16268.29% compared to Checkpoint Therapeutics's net margin of -49.65%. Checkpoint Therapeutics's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

    Company Gross Margin Earnings Per Share Invested Capital
    CKPT
    Checkpoint Therapeutics
    -- -$0.23 -$15.7M
    NBY
    NovaBay Pharmaceuticals
    65.26% -$0.60 $1.1M
  • What do Analysts Say About CKPT or NBY?

    Checkpoint Therapeutics has a consensus price target of $18.00, signalling upside risk potential of 469.62%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $7.30 which suggests that it could grow by 434.43%. Given that Checkpoint Therapeutics has higher upside potential than NovaBay Pharmaceuticals, analysts believe Checkpoint Therapeutics is more attractive than NovaBay Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    CKPT
    Checkpoint Therapeutics
    2 0 0
    NBY
    NovaBay Pharmaceuticals
    2 0 0
  • Is CKPT or NBY More Risky?

    Checkpoint Therapeutics has a beta of 1.361, which suggesting that the stock is 36.073% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.646, suggesting its less volatile than the S&P 500 by 35.372%.

  • Which is a Better Dividend Stock CKPT or NBY?

    Checkpoint Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Checkpoint Therapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CKPT or NBY?

    Checkpoint Therapeutics quarterly revenues are $41K, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Checkpoint Therapeutics's net income of -$9.7M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Checkpoint Therapeutics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Checkpoint Therapeutics is -- versus 0.07x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CKPT
    Checkpoint Therapeutics
    -- -- $41K -$9.7M
    NBY
    NovaBay Pharmaceuticals
    0.07x -- $2.4M -$1.2M
  • Which has Higher Returns CKPT or PTN?

    Palatin Technologies has a net margin of -16268.29% compared to Checkpoint Therapeutics's net margin of -2357.27%. Checkpoint Therapeutics's return on equity of -- beat Palatin Technologies's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    CKPT
    Checkpoint Therapeutics
    -- -$0.23 -$15.7M
    PTN
    Palatin Technologies
    -- -$0.39 -$111.5K
  • What do Analysts Say About CKPT or PTN?

    Checkpoint Therapeutics has a consensus price target of $18.00, signalling upside risk potential of 469.62%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1404.43%. Given that Palatin Technologies has higher upside potential than Checkpoint Therapeutics, analysts believe Palatin Technologies is more attractive than Checkpoint Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    CKPT
    Checkpoint Therapeutics
    2 0 0
    PTN
    Palatin Technologies
    0 0 0
  • Is CKPT or PTN More Risky?

    Checkpoint Therapeutics has a beta of 1.361, which suggesting that the stock is 36.073% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.929%.

  • Which is a Better Dividend Stock CKPT or PTN?

    Checkpoint Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Checkpoint Therapeutics pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CKPT or PTN?

    Checkpoint Therapeutics quarterly revenues are $41K, which are smaller than Palatin Technologies quarterly revenues of $350K. Checkpoint Therapeutics's net income of -$9.7M is lower than Palatin Technologies's net income of -$7.8M. Notably, Checkpoint Therapeutics's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Checkpoint Therapeutics is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CKPT
    Checkpoint Therapeutics
    -- -- $41K -$9.7M
    PTN
    Palatin Technologies
    -- -- $350K -$7.8M
  • Which has Higher Returns CKPT or TOVX?

    Theriva Biologics has a net margin of -16268.29% compared to Checkpoint Therapeutics's net margin of --. Checkpoint Therapeutics's return on equity of -- beat Theriva Biologics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    CKPT
    Checkpoint Therapeutics
    -- -$0.23 -$15.7M
    TOVX
    Theriva Biologics
    -- -$6.81 --
  • What do Analysts Say About CKPT or TOVX?

    Checkpoint Therapeutics has a consensus price target of $18.00, signalling upside risk potential of 469.62%. On the other hand Theriva Biologics has an analysts' consensus of -- which suggests that it could grow by 6141.38%. Given that Theriva Biologics has higher upside potential than Checkpoint Therapeutics, analysts believe Theriva Biologics is more attractive than Checkpoint Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    CKPT
    Checkpoint Therapeutics
    2 0 0
    TOVX
    Theriva Biologics
    0 0 0
  • Is CKPT or TOVX More Risky?

    Checkpoint Therapeutics has a beta of 1.361, which suggesting that the stock is 36.073% more volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.234, suggesting its more volatile than the S&P 500 by 23.367%.

  • Which is a Better Dividend Stock CKPT or TOVX?

    Checkpoint Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Checkpoint Therapeutics pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CKPT or TOVX?

    Checkpoint Therapeutics quarterly revenues are $41K, which are larger than Theriva Biologics quarterly revenues of --. Checkpoint Therapeutics's net income of -$9.7M is lower than Theriva Biologics's net income of -$7.7M. Notably, Checkpoint Therapeutics's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Checkpoint Therapeutics is -- versus 1.59x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CKPT
    Checkpoint Therapeutics
    -- -- $41K -$9.7M
    TOVX
    Theriva Biologics
    1.59x -- -- -$7.7M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Broadcom Stock Overvalued?
Is Broadcom Stock Overvalued?

The semiconductor company Broadcom Inc. (NASDAQ:AVGO) is having a stellar…

4 Top Dividend Stocks to Buy Now
4 Top Dividend Stocks to Buy Now

If you’re looking for steady income, dividend stocks are a…

Will Uber Stock Recover?
Will Uber Stock Recover?

Shares of Uber Technologies (NYSE:UBER) have had a rough few…

Stock Ideas

Sell
48
Is AAPL Stock a Buy?

Market Cap: $3.6T
P/E Ratio: 39x

Sell
47
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 114x

Sell
39
Is MSFT Stock a Buy?

Market Cap: $3.1T
P/E Ratio: 36x

Alerts

Buy
87
CEG alert for Jan 11

Constellation Energy [CEG] is up 25.15% over the past day.

Sell
1
MCY alert for Jan 11

Mercury General [MCY] is down 19.87% over the past day.

Buy
84
ATZAF alert for Jan 11

Aritzia [ATZAF] is up 17.63% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock